The historical rank and industry rank for Can Fite Biopharma's Pretax Margin % or its related term are showing as below:
CANF'
s Pretax Margin % Range Over the Past 10 Years
Min: -5069.12 Med: -1212.3 Max: -171.92
Current: -2425.23
CANF's Pretax Margin % is ranked worse than 84.9% of 947
companies
in the Biotechnology industry
Industry Median: -90.63
vs CANF: -2425.23
Can Fite Biopharma (AMEX:CANF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Can Fite Biopharma Pretax Margin % Related Terms
Can Fite Biopharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CANF vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Can Fite Biopharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (CANF) has a Pretax Margin % of -2,439.41% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Can Fite Biopharma and its competitors. According to the industry distribution chart, Can Fite Biopharma ranks #804 out of 947 companies in the Biotechnology industry, placing it in the top 84.9%.
Is Can Fite Biopharma's Pretax Margin % too high?
Can Fite Biopharma's current Pretax Margin % is -2,439.41%. Based on the distribution chart, Can Fite Biopharma ranks #804 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #804 out of 947 companies for Pretax Margin %. This places Can Fite Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Can Fite Biopharma and its competitors. Can Fite Biopharma's current Pretax Margin % is -2,439.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.98, compared to a current price of $2.99 — trading 50% below its estimated fair value. The current Pretax Margin % is -2,439.41%. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Pretax Margin % is -2,439.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $2.99 is trading 50% below its estimated GF Value™ of $5.98.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
Pretax Margin %: -2,439.41%
GF Value™: $5.98 vs. price of $2.99 (50% below fair value)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score
Get the complete analysis for CANF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
